

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

May 19, 2004

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 18, 2004

Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other
Jurisdiction of
Incorporation)

0-18443
(Commission
File
Number)

52-1574808
(IRS Employer
Identification No.)

8125 North Hayden Road
Scottsdale, Arizona
(Address of Principal
Executive Offices)

85258-2463
(Zip Code)

Registrant's telephone number, including area code: (602) 808-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

=====

Item 2. Acquisition or Disposition of Assets

On May 18, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had closed its previously announced asset purchase agreement and license agreement, and had entered into a securities

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

purchase agreement with BioMarin Pharmaceutical, Inc.

A copy of the Company's press release is attached hereto as Exhibit 99.1.

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated May 18, 2004, issued by Medicis Pharmaceutical Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION (Registrant)

Date: May 18, 2004

/s/ Mark A. Prygocki, Sr.

Name: Mark A. Prygocki, Sr. Title: Executive Vice President, Chief Financial Officer, Corporate Secretary and Treasurer

EXHIBIT INDEX

Table with 2 columns: EXHIBIT NUMBER, DESCRIPTION. Row 1: 99.1 Copy of press release, dated May 18, 2004, issued by Medicis Pharmaceutical Corporation